Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed factors: modest revenue growth, strong ddPCR performance, and strategic M&A focus are positives, yet geopolitical challenges and soft consumable sales are concerns. Unclear management responses and mid-single-digit organic growth decline further neutralize sentiment. The market may react cautiously, but with no drastic movements expected.
Key Financial Performance
Net Sales Net sales for Q1 2026 were approximately $592 million, a 1.1% increase on a reported basis versus $585 million in Q1 2025. On a currency-neutral basis, this represents a 4.2% year-over-year decrease, driven by lower sales in both Life Science and Clinical Diagnostics segments.
Life Science Segment Sales Sales were $229 million in Q1 2026, flat compared to Q1 2025 on a reported basis, and a 4.3% decrease on a currency-neutral basis. This was primarily due to ongoing challenges in the academic research market, particularly in the Americas.
Clinical Diagnostics Segment Sales Sales were approximately $364 million in Q1 2026 compared to $357 million in Q1 2025, an increase of 1.9% on a reported basis, but a decrease of 4.1% on a currency-neutral basis. The decline was primarily driven by revenue declines in the EMEA region due to regional conflicts in the Middle East, which impacted demand and logistics, resulting in an $11 million impact.
Gross Margin Consolidated gross margin was 52.3% for both Q1 2026 and Q1 2025. On a non-GAAP basis, gross margin was 53.1% in Q1 2026 versus 53.8% in Q1 2025. The lower gross margin was due to unfavorable manufacturing absorption from decreased Middle East revenue, higher instruments versus consumables mix, higher freight fuel surcharges, and FX impacts.
SG&A Expense SG&A expense for Q1 2026 was $212 million or 35.9% of sales compared to $209 million or 35.7% in Q1 2025. The increase was primarily due to foreign exchange impacts from a weaker U.S. dollar on the international cost base, partially offset by lower restructuring costs.
R&D Expense R&D expense in Q1 2026 was $63 million or 10.6% of sales compared to $74 million or 12.6% of sales in Q1 2025. On a non-GAAP basis, R&D spend was $65 million in Q1 2026 versus $60 million in Q1 2025.
Operating Income Operating income for Q1 2026 was approximately $34 million compared to $24 million in Q1 2025. On a non-GAAP basis, operating margin was 6.6% in Q1 2026 compared to 10.8% in Q1 2025, reflecting the lower gross margin year-over-year.
Net Income Reported net loss was $527 million or $19.55 per diluted share in Q1 2026, primarily due to a $562 million impact from the change in fair market value of equity security holdings. Non-GAAP net income was $51 million or $1.89 per diluted share in Q1 2026 versus $71 million or $2.54 per diluted share in Q1 2025.
Cash and Short-Term Investments Total cash and short-term investments at the end of Q1 2026 were $1.565 billion compared to $1.541 billion at the end of 2025.
Inventory Inventory at the end of Q1 2026 was $771 million, up from $741 million at the end of 2025.
Operating Cash Flow Net cash generated from operating activities was $108 million in Q1 2026 compared to $130 million in Q1 2025.
Free Cash Flow Free cash flow for Q1 2026 was $78 million compared to $96 million in Q1 2025, representing a free cash flow to non-GAAP net income conversion ratio of 153%.
Share Repurchases During Q1 2026, 176,000 shares were repurchased at a total cost of approximately $48 million. Since Q1 2024, $542 million has been spent to repurchase 2.1 million shares at an average price of approximately $261 per share.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ddPCR instrument revenue: Grew 24% year-over-year, driven by the new QX700 platform, which is enabling competitive wins and conversion from qPCR.
QX700 platform: Ahead of schedule, 99% of digital PCR assays are now supported on this platform, driving instrument growth.
Middle East market: The ongoing conflict in the region has significantly impacted revenue, reducing Q1 2026 revenues and posing a headwind for the full year.
China market: Initiated local manufacturing of select life science instruments to improve responsiveness to local demand and minimize tariff exposure.
Manufacturing flexibility: Increased flexibility by starting local manufacturing in China for the Chinese market.
R&D prioritization: Focused on high-growth clinical applications, leveraging ddPCR technology, and embedding AI capabilities to enhance platform performance.
M&A strategy: Shifted focus to acquiring companies with $100M-$500M revenue range that complement current business, aiming for disciplined, targeted, and accretive growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Geopolitical Conflict in the Middle East: The ongoing conflict in the Middle East has significantly reduced revenues, particularly in the Diagnostics segment, which represented over 9% of the segment's revenue in 2025. This conflict has disrupted demand and logistics, creating a substantial headwind for revenue and margin for 2026.
Academic Research Funding Challenges: Academic demand, particularly in the Americas, remains constrained due to changes in funding. Despite a modest increase in NIH funding, there is considerable disruption and a lag between funding approvals and purchasing activity, negatively impacting the Life Science segment.
Supply Chain Cost Pressures: The Diagnostics segment has been adversely affected by supply chain cost pressures, including higher freight fuel surcharges and unfavorable manufacturing absorption due to decreased revenue from the Middle East.
Currency Exchange Impact: Foreign exchange fluctuations, particularly a weaker U.S. dollar, have increased SG&A expenses and impacted international cost bases.
Biopharma Market Caution: Early-stage biotech companies remain cautious, leading to softer biopharma consumables demand despite some stabilization in later-stage companies. This impacts the Life Science segment's revenue growth.
Manufacturing and Operational Challenges: Efforts to rationalize manufacturing capacity and network are ongoing to address supply chain challenges. Additionally, the company is increasing flexibility in its manufacturing footprint, such as producing select instruments in China for local markets, to improve responsiveness and minimize tariff exposure.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has adjusted its 2026 guidance due to ongoing conflict in the Middle East. Full-year currency-neutral revenue growth is expected to be between -3% and +0.5%. Life Science segment revenue growth is projected to be between -3% and -1%, while the Diagnostics segment is expected to grow between -3% and +1%.
Market Recovery Expectations: The company anticipates a gradual recovery in the Life Science segment, led by biopharma, despite challenges in academic funding and geopolitical disruptions.
Product and Technology Development: The digital PCR product area, particularly the QX700 platform, is expected to drive growth and margin expansion. The company is focusing on high-growth clinical applications, advancing its digital PCR portfolio, and embedding AI capabilities to enhance platform performance.
Operational Adjustments: The company is increasing flexibility in its manufacturing footprint, including manufacturing select life science instruments in China for local demand. This is expected to improve responsiveness and minimize tariff exposure.
Margin Projections: Full-year non-GAAP gross margin is projected to be between 53% and 54%, with operating margin expected to be between 10% and 12%. Margin pressures are attributed to lower revenue, higher freight rates, and unfavorable manufacturing absorption.
Capital Expenditures and Free Cash Flow: Full-year free cash flow is estimated to be in the range of $290 million to $340 million. The company plans to continue opportunistic share repurchases.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Buyback Program: During the first quarter of 2026, Bio-Rad repurchased 176,000 shares through its buyback program at a total cost of approximately $48 million. Since Q1 of 2024, the company has spent $542 million to repurchase 2.1 million shares at an average price per share of approximately $261.
Remaining Buyback Authorization: As of March 31, 2026, Bio-Rad has approximately $237 million available for additional buybacks under the current Board-authorized program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the impact of the Middle East conflict on Bio-Rad's business?
A:The Middle East is a fast-growing region for Bio-Rad, contributing 9% to the Diagnostics business and mid-single digits to the company overall. The conflict has slowed down the channel, leading to missed revenue expectations. Bio-Rad had anticipated high double-digit growth in the region, but the conflict has caused a break in growth. Recovery will take time, and the new guidance reflects this situation.
Q:What cost actions is Bio-Rad planning to take to protect and grow earnings in the current environment?
A:Bio-Rad is evaluating several actions, including reducing discretionary spending. If the impact of external challenges continues, more significant actions may be taken. The company is also considering structural changes to improve efficiency and agility in response to ongoing challenges like tariffs and the Middle East conflict. Specific details are not yet available.
Q:What is the update on the China diagnostics business and the NHSA's new cost containment strategies?
A:To date, Bio-Rad has not observed any impact from the NHSA's new cost containment strategies in China. The company will continue to monitor and evaluate the situation.
Q:What is the revenue phasing expectation for Q2 and Q3?
A:Q1 is typically the lowest quarter, with a 5% revenue lift expected from Q1 to Q2. Q3 is expected to see a slight increase from Q2, which has been flat in previous years. Q4 is anticipated to be the strongest quarter. Specific drivers include strong quality controls in Q3 and Q4 and an uptick in the blood typing business in other regions.
Q:What is the performance of the ddPCR business, and what are the competitive dynamics?
A:Instrument sales for QX700 and legacy QX200 systems are strong. However, consumables, which form the majority of the business, were soft due to academic and biopharma project delays. The company is growing its installed base and taking share from qPCR. The ddPCR portfolio is the healthiest it has been in some time, with an expanding pipeline and increasing publications.
Q:What are Bio-Rad's M&A priorities?
A:M&A is part of Bio-Rad's strategy to grow the business alongside organic growth. The company is focusing on developing the business and considers M&A as a complementary piece of the strategy. No specific actionable items were disclosed.
Q:What is the company's approach to R&D spending and ROI?
A:Bio-Rad is spending 12% on R&D, which is high compared to peers. The company is focusing on bringing products to market faster and achieving better ROI. Efforts include applying AI to imaging platforms, managing the life cycle of the existing portfolio, and making large bets in diagnostics. Over time, the company aims to become more efficient and reduce R&D spending while maintaining a robust innovation pipeline.
Q:What is the guidance for Q2 organic growth?
A:The company expects Q2 organic growth to be down mid-single digits (around 5-6%). Revenue is expected to increase slightly, but gross margin will dip due to increased freight costs related to the Middle East conflict.
Q:What is the outlook for operating margins and actions to improve them?
A:Bio-Rad is committed to driving operating margin expansion. Near-term actions include mitigating increased costs like fuel and logistics. Broader evaluations and actions are ongoing, and the company is focused on improving operations and capabilities to adapt to market conditions.
Q:What is the performance and visibility of the process chromatography business?
A:The process chromatography business performed as expected in Q1. The company is monitoring customer order patterns and demand. While there is some revenue concentration, Bio-Rad is working on diversifying revenue sources by participating in several hundred projects across different stages of clinical trials. The path to recovery is expected to be low single-digit growth next year, with a gradual return to mid-single-digit growth.
Q:What is the competitive landscape and growth outlook for the digital PCR business?
A:Bio-Rad feels confident in its digital PCR business. The commercial and marketing teams are working effectively, and the portfolio is being well-received by customers. The company is expanding its assay offerings and believes it is in a stronger position compared to the previous year.
Q:What are the assumptions for the biopharma end market?
A:The biopharma market is segmented into large pharmaceutical companies, smaller biotechs with late-stage molecules, and early-stage biotechs. Large companies and late-stage biotechs are performing well, while early-stage biotechs remain conservative in spending. Bio-Rad sees strength in some areas but softness in others.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the structural changes being considered to improve efficiency and agility. They also did not elaborate on actionable M&A opportunities or provide precise metrics for R&D ROI improvements. Additionally, the response to the question about the path to recovery for process chromatography lacked detailed visibility into the timeline and specific actions being taken.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Americas
Bio Rad
Diagnostics segment
East conflict
East region
Middle East
Rad Head
Regina
SGA expense
Science segment
action
assay QX
base
basis decrease
basis point
biopharma
capability
cash flow
challenge
change equity
chromatography currency
conflict Middle
conflict region
conversion
demand logistics
digit
efficiency
environment
freight
instrument indicator
name
non
portfolio
pressure
prioritization
priority
stage
supply chain
team
BIO Transcript
Bio-Rad Laboratories, Inc. (BIO) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Neutral5-19
Bio-Rad Laboratories, Inc. (BIO) Q1 2026 Earnings Call Transcript
Unknown5-1
The earnings call reveals mixed factors: modest revenue growth, strong ddPCR performance, and strategic M&A focus are positives, yet geopolitical challenges and soft consumable sales are concerns. Unclear management responses and mid-single-digit organic growth decline further neutralize sentiment. The market may react cautiously, but with no drastic movements expected.
Bio-Rad Laboratories, Inc. (BIO) Q4 2025 Earnings Call Transcript
Unknown2-12
The earnings call presents a mixed picture: modest revenue growth in diagnostics and improved free cash flow contrast with declining margins and net income. The Q&A reveals cautious management guidance and uncertainties in process chromatography. Despite strong growth in ddPCR and cash reserves, the lack of buyback and management's vague responses temper optimism. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Earnings Call Transcript
Unknown10-29
The earnings call presents a mixed picture: while there is optimism in product development and partnerships, financial metrics show declining cash flow and net loss. The guidance is cautious, with some positive outlooks, but uncertainties in key markets like China and the Americas persist. The Q&A reveals optimism in certain areas, but management's vague responses on growth and market challenges add uncertainty, balancing positive developments. Overall, the sentiment remains neutral as positive and negative factors offset each other.
BIO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
